Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth

Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Jg. 76; H. 23; S. 6924
Hauptverfasser: Lin, Huai-Peng, Cheng, Zhou-Li, He, Ruo-Yu, Song, Lei, Tian, Meng-Xin, Zhou, Li-Sha, Groh, Beezly S, Liu, Wei-Ren, Ji, Min-Biao, Ding, Chen, Shi, Ying-Hong, Guan, Kun-Liang, Ye, Dan, Xiong, Yue
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.12.2016
Schlagworte:
Acetylation
Cell Growth Processes - genetics
Cell Proliferation
Fatty Acid Synthases - genetics
Humans
Lipogenesis - genetics
Signal Transduction
Tumor Microenvironment
ISSN:1538-7445, 1538-7445
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924-36. ©2016 AACR.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1538-7445
1538-7445
DOI:10.1158/0008-5472.can-16-1597